Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Sai Life Sciences names winners of Biotech Pitch Day 2026

By R&D World | April 8, 2026

Participants at Sai Life Sciences' Biotech Pitch Day 2026, held at the company's Boston-area site. (Photo: Sai Life Sciences)

Participants at Sai Life Sciences’ Biotech Pitch Day 2026, held at the company’s Boston-area site. (Photo: Sai Life Sciences)

Sai Life Sciences recently hosted its Biotech Pitch Day 2026 at the company’s Boston-area site, with 10 early-stage biotech companies presenting to a judge panel that included Daniel Resnicow, operating partner at Engine Ventures; Stephanos Ioannidis, who leads the Modalities Innovation Lab at Astellas Pharma; independent R&D executive Bharat Lagu; and Arjun Goyal, founder and managing partner at Vianti Capital.

Three finalists were recognized for scientific rigor and vision: Block Biosciences, Neuropathix and Zena Therapeutics. Cryptyx Bioscience and Tag Team Therapeutics received additional recognition for their pitches.

Block Biosciences is developing small-molecule therapies paired with companion diagnostics intended to identify high-risk patients and intervene before cancer cells colonize the brain. The company’s focus is on preventing metastatic spread to the CNS rather than treating brain metastases after they form.

Neuropathix is advancing synthetic cannabinoid-inspired therapeutics aimed at interconnected pathways including neuroinflammation and mitochondrial dysfunction. Its lead candidate, KLS-13019, is designed to act on multiple targets: mNCX-1, GPR55, and the NLRP3 inflammasome. The company positions the multi-target approach as a differentiator from single-mechanism treatments.

Zena Therapeutics is developing ZTX-001, a compound designed to match the rapid efficacy of benzodiazepines in treating anxiety while avoiding the addiction, overdose, and withdrawal risks associated with that drug class.

Sai Life Sciences Executive Vice President and Head of Discovery Services Maneesh Pingle said in a statement: “We were encouraged by the quality of science and the diversity of ideas presented, and by the openness with which founders engaged in dialogue. Beyond identifying promising programs, the event was about building connections—and we see this as the beginning of several meaningful collaborations.”

The full finalist cohort, selected competitively from a broader applicant pool, included Zena Therapeutics, Luciole Pharmaceuticals, NuCyRNA Therapeutics, Myracle Therapeutics, AudazBio, Block Biosciences, Weld Pharmaceuticals, Cryptyx Bioscience, Vistara Bioscience and Neuropathix.

Selected startups will have the opportunity to collaborate with Sai Life Sciences and access its integrated drug discovery platform. Maneesh Pingle, executive vice president and head of discovery services, characterized the event as “the beginning of several meaningful collaborations.”

Sai Life Sciences is a global contract research, development, and manufacturing organization (CRDMO) that works with biotech and pharmaceutical companies on drug discovery, development and commercialization. R&D World recently profiled the company’s Integrated R&D Campus in Hyderabad, a 12-acre site that co-locates medicinal chemistry, biology, DMPK and process development teams, and where Sai broke ground last October on a new CMC Process R&D Center scheduled for completion in September 2026.

Finalists, judges, and Sai Life Sciences leadership gather at Biotech Pitch Day 2026. (Photo: Sai Life Sciences)

Finalists, judges, and Sai Life Sciences leadership gather at Biotech Pitch Day 2026. (Photo: Sai Life Sciences)


Filed Under: Biotech

 

Related Articles Read More >

The 50 best-funded biotech companies of 2026
Novo Nordisk in the Drug Discovery & Development Pharma 50
Novo Nordisk’s ziltivekimab misses Phase 3 primary endpoint 
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
Blazing new paths for biotech
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE